FDA approves Ztalmy, first treatment specifically for CDD

19 March 2022
marinus_company-1-

The US Food and Drug Administration on Friday said it has approved Ztalmy (ganaxolone) to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two years of age and older.

Developed by USA-based rare seizure specialist Marinus Pharmaceuticals (Nasdaq: MRNS), this is the first treatment for seizures associated with CDD and the first treatment specifically for CDD. The news saw Marinus’ shares rocket almost 50% to $11.54.

The company said Ztalmy is expected to be commercially available in the USA in July following scheduling by the US Drug Enforcement Administration. Ztalmy has been priced at $2,425 per bottle, or $133,000 per year. With discounts, it will cost $105,000 per patient for a year’s treatment.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical